Hohoff Christa, Garibotto Valentina, Elmenhorst David, Baffa Anna, Kroll Tina, Hoffmann Alana, Schwarte Kathrin, Zhang Weiqi, Arolt Volker, Deckert Jürgen, Bauer Andreas
Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.
Institute of Neuroscience and Medicine (INM-2), Forschungszentrum Jülich, Jülich, Germany.
Neuropsychopharmacology. 2014 Dec;39(13):2989-99. doi: 10.1038/npp.2014.150. Epub 2014 Jun 19.
Adenosine A1 receptors (A1ARs) and the interacting adenosine A2A receptors are implicated in neurological and psychiatric disorders. Variants within the corresponding genes ADORA1 and ADORA2A were shown associated with pathophysiologic alterations, particularly increased anxiety. It is unknown so far, if these variants might modulate the A1AR distribution and availability in different brain regions. In this pilot study, the influence of ADORA1 and ADORA2A variants on in vivo A1AR binding was assessed with the A1AR-selective positron emission tomography (PET) radioligand [(18)F]CPFPX in brains of healthy humans. Twenty-eight normal control subjects underwent PET procedures to calculate the binding potential BPND of [(18)F]CPFPX in cerebral regions and to assess ADORA1 and ADORA2A single nucleotide polymorphism (SNP) effects on regional BPND data. Our results revealed SNPs of both genes associated with [(18)F]CPFPX binding to the A1AR. The strongest effects that withstood even Bonferroni correction of multiple SNP testing were found in non-smoking subjects (N=22) for ADORA2A SNPs rs2236624 and rs5751876 (corr. Pall<0.05). SNP alleles previously identified at risk for increased anxiety like the rs5751876 T-allele corresponded to consistently higher A1AR availability in all brain regions. Our data indicate for the first time that variation of A1AR availability was associated with ADORA SNPs. The finding of increased A1AR availability in regions of the fear network, particularly in ADORA2A risk allele carriers, strongly warrants evaluation and replication in further studies including individuals with increased anxiety.
腺苷A1受体(A1ARs)以及与之相互作用的腺苷A2A受体与神经和精神疾病有关。相应基因ADORA1和ADORA2A中的变异体已显示与病理生理改变相关,尤其是焦虑增加。到目前为止,尚不清楚这些变异体是否可能调节不同脑区的A1AR分布和可用性。在这项初步研究中,使用A1AR选择性正电子发射断层扫描(PET)放射性配体[(18)F]CPFPX评估了ADORA1和ADORA2A变异体对健康人脑中体内A1AR结合的影响。28名正常对照受试者接受了PET检查,以计算[(18)F]CPFPX在脑区的结合潜能BPND,并评估ADORA1和ADORA2A单核苷酸多态性(SNP)对区域BPND数据的影响。我们的结果显示,两个基因的SNP都与[(18)F]CPFPX与A1AR的结合有关。在非吸烟受试者(N = 22)中,发现ADORA2A SNP rs2236624和rs5751876具有最强的效应,即使经过多重SNP测试的Bonferroni校正也能承受(校正后Pall<0.05)。先前确定有焦虑增加风险的SNP等位基因,如rs575l876 T等位基因,在所有脑区中始终对应于更高的A1AR可用性。我们的数据首次表明,A1AR可用性的变化与ADORA SNP相关。在恐惧网络区域,特别是在ADORA2A风险等位基因携带者中,A1AR可用性增加的发现强烈需要在包括焦虑增加个体的进一步研究中进行评估和重复验证。